New pharma startups have more non-dilutive funding opportunities than they may realize–they just have to know where to look and open their minds.
Sometimes, US-based small startups find their evolving R&D plan, funding, or business collaborations make them suddenly ineligible for SBIR funding they had targeted. For example, clinical trial costs or even lab work would be cheaper overseas, so, just like that, eligibility slips away.
What to do? Continue reading “The EU’s World-Class R&D Funding and Support for Innovators”
The new year is a great time to recommit to your funding pursuit and do some deep work on crafting a funding strategy and drafting some proposals, but that energy will be misspent if you haven’t spent some time catching up with NIH policies effective in the new year. So here are 4 great sources for news everyone applying for funding should know.
Updated 12 December 2017.
Just a quick reminder to everyone to set some time aside over the holidays to review changes to NIH policy (e.g., clinical trials) before drafting a funding strategy for 2018. The new year is a great time to recommit to your funding pursuit and do some deep work on crafting a funding strategy and drafting some proposals, but that energy will be misspent if you haven’t spent some time catching up with NIH policies effective in the new year. So here are 4 great sources for news everyone applying for funding should know. Continue reading “4 Quick Ways to Catch up on Critical Changes to Federal Grant Applications and Processes”
Strategic Grantsmanship 